RxDoctor Payments Data

Wallace Wang, MD

Gastroenterology · New York, NYNPI 1598924805

Payments from drug & device makers

$134,855in general payments, 2019–2025

Across 463 payments — averaging $291.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$126K
  • AbbVie$4K
  • Ardelyx, Inc.$1K
  • Madrigal Pharmaceuticals$777
  • Nestle Healthcare Nutrition Inc.$492
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$490
  • plus $2K from 17 others

What the payments were for

  • Consulting fees$5,5604%
  • Speaking & faculty fees$107,49680%
  • Travel & lodging$7,6016%
  • Food & beverage$14,18311%
  • Education$150%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$134,855 in reported general payments places this provider in the 90th percentile of 1,682 gastroenterology providers in New York.

See all gastroenterology providers in New York

Medicare billing

Part B allowed, 2024
$41,595
Medicare patients
131
Services billed
271

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VemlidyTenofovir Alafenamide86$144,157
CreonLipase/Protease/Amylase26$68,613
LinzessLinaclotide90$50,403
Omeprazole-Sodium BicarbonateOmeprazole/Sodium Bicarbonate12$19,147
SutabSod Sulf/Pot Chloride/Mag Sulf85$13,718
Mesalamine46$12,406
Dexlansoprazole DrDexlansoprazole53$11,493
VoqueznaVonoprazan Fumarate11$7,043
Famotidine698$5,673
Budesonide ErBudesonide12$5,553
Entecavir11$5,177
Esomeprazole Magnesium137$4,432
Omeprazole543$4,279
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates25$1,377
Pantoprazole Sodium229$1,191

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadVemlidy$126,136$144,15786 claims
AbbVieCreon, Linzess$3,655$119,016116 claims
Braintree Laboratories, Inc.Sutab$20$13,71885 claims
Phathom Pharmaceuticals, Inc.Voquezna$423$7,04311 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,682 gastroenterology providers in New York.

Other gastroenterology in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →